Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Peptide Process CMCPeptide Process CMC
Not Confirmed
Not Confirmed
28-30 August, 2025
Not Confirmed
Not Confirmed
01-03 September, 2025
Process DevelopmentProcess Development
Not Confirmed
Not Confirmed
01 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Peptide Process CMCPeptide Process CMC
Industry Trade Show
Not Confirmed
28-30 August, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
Process DevelopmentProcess Development
Industry Trade Show
Not Confirmed
01 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
31 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250731800519/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-and-Six-Months-Ended-June-30-2025
22 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250722543875/en/Aurinia-Pharmaceuticals-to-Release-Second-Quarter-2025-Financial-and-Operational-Results-on-July-31-2025
30 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250630928719/en/Aurinia-Announces-Positive-Results-from-Phase-1-Study-of-Aritinercept-AUR200
29 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250629847355/en/Aurinia-Pharmaceuticals-to-Host-Conference-Call-to-Discuss-AUR200-Phase-1-Study-Results-on-June-30-2025
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522481716/en/New-AURORA-1-Analysis-LUPKYNIS-Based-Triple-Immunosuppressive-Therapy-Yields-Deep-Proteinuria-Reduction-in-Lupus-Nephritis
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025
ABOUT THIS PAGE